Conference Reports for NaTaP

EASL - The International Liver Congress 2015 50th annual Meeting of the European association for the Study of the Liver Vienna, austria  april 22-26 Back

8 HCV DAA Studies in African-Americans       - Similar SVR Rates Among Black & Non-Black Patients with or without Cirrhosis AASLD/2014: Safety and Efficacy of LDV/SOF in African Americans: A Retrospective Analysis of Phase 3 Data - (11/12/14)   AASLD/2014: Use of Ledipasvir/Sofosbuvir Fixed Dose Combination for Treatment of HCV Genotype-1 Infection in Patients Coinfected with HIV - Eradicate Study - (11/10/14) 98% SVR, 80% African-Americans AASLD/2014: Efficacy by Race or Geographic Region in HCV Genotype 1-Infected Patients Treated With ABT-450/Ritonavir/Ombitasvir and Dasabuvir With or Without Ribavirin - (11/14/14)   EASL/2015: THE PHASE 3 C-EDGE TREATMENT-NAIVE (TN) STUDY OF A 12-WEEK ORAL REGIMEN OF GRAZOPREVIR (GZR, MK-5172)/ELBASVIR (EBR, MK-8742) IN PATIENTS WITH CHRONIC HCV GENOTYPE (GT) 1, 4, OR 6 INFECTION - (04/24/15)   EASL: Daclatasvir Plus Sofosbuvir for Treatment of HCV Genotypes 1-4 in HIV-HCV Coinfection: The ALLY-2 Study - (04/23/15)   CROI: Daclatasvir in Combination With Sofosbuvir for HIV/HCV Coinfection: ALLY-2 Study - (02/27/15)   CROI: Ledipasvir/sofosbuvir for 12 Weeks in Patients Coinfected With HCV and hiv-1: ION-4 - (02/27/15)   EASL: A Single-Tablet Regimen of Ledipasvir/Sofosbuvir for 12 Weeks in HCV Genotype 1- or 4-Infected Patients With HIV-1 Coinfection: the Phase 3 ION-4 Study - (04/28/15)